Publications

You can find a full list of Bruce Vallance’s publications here.

• Deep phenotyping of infants and toddlers undergoing food oral immunotherapy (DINOSAUR): design and baseline characteristics of a prospective multi-omics cohort
  August 12, 2026 by Ann-Marie Malby Schoos
• Host-microbe Interactions in the Appendix of Children with Inflammatory Bowel Diseases
  July 30, 2026 by Nazanin Arjomand Fard
• The growth and pathogenesis of Citrobacter rodentium are compromised when multiple mucin sugar utilization pathways are disrupted, leading to accumulation of N-acetylglucosamine 6-phosphate
  March 16, 2026 by Zhiquan Clarence Huang
• Biopsy-derived colonoid air-liquid interface monolayers reveal persistent mucosal defects in ulcerative colitis patients
  January 27, 2026 by Ashley Gilliland
• In mouse and in vitro models, bowel preparation promotes pathogen colonization, translocation, and exacerbation of inflammation
  December 23, 2025 by Charlotte A Clayton
• Differential roles for Irgm1 in myeloid cells for immune resistance to pathogenic bacteria
  November 20, 2025 by Brian E Fee
• Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients
  August 29, 2025 by Franziska A Graef
• TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation
  August 20, 2025 by Karoliina Tuomela
• Nociceptor neurons suppress alveolar macrophage-induced Siglec-F+ neutrophil-mediated inflammation to protect against pulmonary fibrosis
  May 31, 2025 by Carlos H Hiroki
• Crosstalk with infant-derived Th17 cells, as well as exposure to IL-22 promotes maturation of intestinal epithelial cells in an enteroid model
  May 16, 2025 by Zohreh Sharafian
• Defining enteric bacterial pathogenesis using organoids: Citrobacter rodentium uses EspC, an atypical mucinolytic protease, to penetrate mouse colonic mucus
  May 5, 2025 by Yan Chen
• The gut-skin axis: a bi-directional, microbiota-driven relationship with therapeutic potential
  March 6, 2025 by Maira Jimenez-Sanchez
• Development of novel GI-centric prostaglandin E2 receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases
  January 10, 2025 by Srinivas Kantham
• MUC17 is an essential small intestinal glycocalyx component that is disrupted in Crohn's disease
  December 19, 2024 by Elena Layunta
• Inflammasome activation links enteric Salmonella Typhimurium infection to a rapid, cytokine-dependent increase in intestinal mucin release
  October 21, 2024 by Xiao Han